Datathons

Datathons

 

The sbv IMPROVER Datathon 2017 will gather data scientists, bioinformaticians and computational biologists to turn data into knowledge. The aim will be to biologically interpret and quantify Omics measurements from an 8-month inhalation toxicology study and an in vitro organotypic nasal acute exposure study assessing THS2.2, a candidate Reduced-Risk Product*.

Japan datathon

 This event will be held in Tokyo on October 13th.

Join the Datathon to:

  • Earn a 15,000 JPY voucher;
  • Present the method applied in your submission at the Symposium;
  • Present your own research during a poster session at the Symposium;
  • Learn from each other and exchange on computational methods;
  • Co-author scientific articles describing the outcome of the challenge;
  • Have fun! 

 

Download the flyer in English or in Japanese for more details and visit the dedicated event website to register!

 

Datathon conduct

 

 

 Past Datathons:

 

Banner datathon

 

The sbv IMPROVER Datathon 2016 gathered computational biologists to turn data into knowledge. The provided datasets will be Omics and functional measurements from a 7-month inhalation toxicology study.

 This event was held in Singapore on September 23rd and 24th 2016 in the Park Avenue Rochester Hotel.

Join the Datathon to:

Have your method published as a Garuda gadget; Learn from each other and exchange on computational methods; Co-author the event outcome publication; Have fun!

 

Download the flyer for more details and visit the dedicated event website to register!

 

 

*Reduced Risk Products (“RRPs”) is the term we use to refer to products with the potential to reduce individual risk and population harm in comparison to smoking cigarettes. PMI’s RRPs are in various stages of development and commercialization, and we are conducting extensive and rigorous scientific studies to determine whether we can support claims for such products of reduced exposure to harmful and potentially harmful constituents in smoke, and ultimately claims of reduced disease risk, when compared to smoking cigarettes. Before making any such claims, we will rigorously evaluate the full set of data from the relevant scientific studies to determine whether they substantiate reduced exposure or risk. Any such claims may also be subject to government review and authorization, as is the case in the USA today.

 

 

Share this page